New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 14, 2013
07:08 EDTSPPI, LGNDSpectrum gains rights to Capitsol-enabled Melphalan
Spectrum Pharmaceuticals (SPPI) has gained global development and commercialization rights to Ligand Pharmaceuticals’ (LGND) Captisol-enabled, propylene glycol-free (PG-free) melphalan. Captisol-enabled melphalan is currently in a pivotal trial for use as a conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma. Spectrum is assuming the responsibility for the ongoing pivotal clinical trial and will be responsible for filing an NDA, which is anticipated in the first half of 2014. Under the license agreement, Ligand will receive a license fee and is eligible to receive milestone payments, as well as royalties following potential commercialization.
News For SPPI;LGND From The Last 14 Days
Check below for free stories on SPPI;LGND the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
09:33 EDTLGNDGlaxoSmithKline reports record Promacta/Revolade Q2 revenue of $92M
Subscribe for More Information
July 22, 2014
13:17 EDTLGNDLigand reports partner SAGE receives fast track designation for SAGE-547
Subscribe for More Information
July 17, 2014
08:02 EDTLGNDLigand sees Q2 revenue $10.6M, above previous guidance of $9M-$9.5M
Subscribe for More Information
08:01 EDTLGNDLigand board authorizes $10M repurchase program
Subscribe for More Information
July 16, 2014
09:41 EDTLGNDLigand management to meet with Roth Capital
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use